Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine
暂无分享,去创建一个
[1] A. Kapsoritakis,et al. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity , 2012, Journal of Gastroenterology.
[2] P. Rutgeerts,et al. Laboratory markers in IBD: useful, magic, or unnecessary toys? , 2006, Gut.
[3] I. Dale,et al. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. , 1980, Bulletin europeen de physiopathologie respiratoire.
[4] P. Rutgeerts,et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. , 2003, Gastroenterology.
[5] A. Vaiopoulou,et al. Serum protein profile of Crohn's disease treated with infliximab. , 2013, Journal of Crohn's & colitis.
[6] A. Røseth,et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. , 1992, Scandinavian journal of gastroenterology.
[7] A. Darzi,et al. Diagnostic Precision of Anti-Saccharomyces cerevisiae Antibodies and Perinuclear Antineutrophil Cytoplasmic Antibodies in Inflammatory Bowel Disease , 2006, The American Journal of Gastroenterology.
[8] P. Hoff,et al. Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib , 2014, British Journal of Cancer.
[9] Igor M. Dozmorov,et al. Identification of Unique MicroRNA Signature Associated with Lupus Nephritis , 2010, PloS one.
[10] S. Kugathasan,et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease , 2008, Inflammatory bowel diseases.
[11] Mei Zhao,et al. Identification of a Circulating MicroRNA Signature for Colorectal Cancer Detection , 2014, PloS one.
[12] J. Mate,et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse , 2009, Inflammatory bowel diseases.
[13] Keith W. Jones,et al. Genome-Wide Maps of Circulating miRNA Biomarkers for Ulcerative Colitis , 2012, PloS one.
[14] A. Røseth,et al. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease , 2004, Scandinavian journal of gastroenterology.
[15] A. Day,et al. S100A12: A noninvasive marker of inflammation in inflammatory bowel disease , 2013, Journal of digestive diseases.
[16] Philippe Seksik,et al. Epidemiology and natural history of inflammatory bowel diseases. , 2011, Gastroenterology.
[17] P. Malfertheiner,et al. Feasibility of Fecal MicroRNAs as Novel Biomarkers for Pancreatic Cancer , 2012, PloS one.
[18] S. Brant,et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. , 2008, Gastroenterology.
[19] S. Brant,et al. Peripheral blood MicroRNAs distinguish active ulcerative colitis and Crohn's disease , 2011, Inflammatory bowel diseases.
[20] I. Leodolter. [Crohn's disease]. , 1967, Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete.
[21] P. Geurts,et al. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. , 2008, Clinical biochemistry.
[22] A. Chinnaiyan,et al. MicroRNA expression patterns in indeterminate inflammatory bowel disease , 2013, Modern Pathology.
[23] M. Leonard,et al. Circulating MicroRNA Is a Biomarker of Pediatric Crohn Disease , 2011, Journal of pediatric gastroenterology and nutrition.
[24] W. Sjursen,et al. Identification of serum microRNA profiles in colon cancer , 2013, British Journal of Cancer.
[25] M. Camilleri,et al. Fecal Lactoferrin Is a Sensitive and Specific Marker in Identifying Intestinal Inflammation , 2003, American Journal of Gastroenterology.
[26] F. Marabita,et al. Identification of serum and tissue micro‐RNA expression profiles in different stages of inflammatory bowel disease , 2013, Clinical and experimental immunology.
[27] E. Chan,et al. Global fecal microRNA profiling in the identification of biomarkers for colorectal cancer screening among Asians. , 2014, Oncology reports.
[28] J. Jahnsen,et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. , 1997, Digestion.
[29] M. Neurath,et al. Mouse models of inflammatory bowel disease. , 2007, Advanced drug delivery reviews.
[30] C. Boland,et al. Fecal MicroRNAs as Novel Biomarkers for Colon Cancer Screening , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[31] D. Foell,et al. Neutrophil-derived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease. , 2004, The American journal of cardiology.
[32] S. Ng,et al. Geographical variability and environmental risk factors in inflammatory bowel disease , 2013, Gut.
[33] A. Zinsmeister,et al. Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.
[34] O. Nielsen,et al. miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis. , 2013, World journal of gastroenterology.
[35] Zhongmin Liu,et al. C-Reactive Protein in Human Atherogenesis: Facts and Fiction , 2014, Mediators of inflammation.
[36] Carsten Peterson,et al. Detection of pancreatic cancer using antibody microarray‐based serum protein profiling , 2008, Proteomics.
[37] Y. Naito,et al. Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis , 2010, Journal of gastroenterology and hepatology.
[38] David Westhead,et al. Prediction of clinical outcome in glioblastoma using a biologically relevant nine‐microRNA signature , 2015, Molecular oncology.
[39] M. Lentze,et al. Fecal Lactoferrin: A New Parameter to Monitor Infliximab Therapy , 2004, Digestive Diseases and Sciences.
[40] P. Bakke,et al. Neutrophil gelatinase-associated lipocalin: a biomarker in COPD. , 2010, Chest.
[41] M. Färkkilä,et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti‐TNF‐alpha therapy for Crohn's disease , 2008, Inflammatory bowel diseases.
[42] M. Färkkilä,et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment , 2010, Scandinavian journal of gastroenterology.
[43] R. Stock,et al. C‐reactive protein is significantly associated with prostate‐specific antigen and metastatic disease in prostate cancer , 2005, BJU international.
[44] Heng-jun Gao,et al. Aberrant expression of microRNAs in serum may identify individuals with pancreatic cancer. , 2014, International journal of clinical and experimental medicine.
[45] M. Bottai,et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease , 2005, Gut.
[46] C. Geczy,et al. S100 Calgranulins in inflammatory arthritis , 2010, Immunology and cell biology.
[47] L. Du,et al. Serum microRNA expression signatures identified from genome‐wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer , 2015, International journal of cancer.
[48] G. Heinze,et al. Serum C-reactive protein in the differential diagnosis of ovarian masses. , 2009, European journal of obstetrics, gynecology, and reproductive biology.
[49] Thomas Francis,et al. SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS , 1930, The Journal of experimental medicine.
[50] A. Schetter,et al. Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. , 2015, Journal of the National Cancer Institute.
[51] R. Donato,et al. Intracellular and extracellular roles of S100 proteins , 2003, Microscopy research and technique.
[52] Linda S. Lee,et al. A microRNA-based test improves endoscopic ultrasound-guided cytologic diagnosis of pancreatic cancer. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[53] A. Young,et al. Fecal Lipocalin 2, a Sensitive and Broadly Dynamic Non-Invasive Biomarker for Intestinal Inflammation , 2012, PloS one.
[54] K. Pienta,et al. Circulating microRNA Profiling Identifies a Subset of Metastatic Prostate Cancer Patients with Evidence of Cancer-Associated Hypoxia , 2013, PloS one.
[55] Bo Xiao,et al. Longitudinal study of circulating protein biomarkers in inflammatory bowel disease. , 2015, Journal of proteomics.
[56] D E McMillan,et al. Increased levels of acute-phase serum proteins in diabetes. , 1989, Metabolism: clinical and experimental.
[57] S. Targan,et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. , 1998, Gastroenterology.
[58] I. Bjarnason,et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.
[59] M. Bertagnolli,et al. Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance) , 2013, Clinical Cancer Research.
[60] P. Geurts,et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. , 2007, Biochemical pharmacology.
[61] M. Lewandowska,et al. Prognostic and Predictive Biomarkers: Tools in Personalized Oncology , 2014, Molecular Diagnosis & Therapy.
[62] M. Casale,et al. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. , 2007, Rapid communications in mass spectrometry : RCM.
[63] A. Petrie,et al. Immunological studies in inflammatory bowel disease. , 1977, Ciba Foundation symposium.
[64] A. Day,et al. Fecal S100A12: A novel noninvasive marker in children with Crohn's disease , 2006, Inflammatory bowel diseases.
[65] Stephen A. Williams,et al. Validation of a blood protein signature for non-small cell lung cancer , 2014, Clinical Proteomics.
[66] M. Gazouli,et al. Circulating MicroRNA in inflammatory bowel disease. , 2012, Journal of Crohn's & colitis.
[67] A. Griffiths,et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response , 2010, Gut.
[68] J. Schölmerich,et al. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. , 1990, Immunobiology.
[69] M. Bissonnette,et al. miR‐143 and miR‐145 are downregulated in ulcerative colitis: Putative regulators of inflammation and protooncogenes , 2012, Inflammatory bowel diseases.
[70] C. Borrebaeck,et al. Identification of serum biomarker signatures associated with pancreatic cancer. , 2012, Cancer research.
[71] S. Fais,et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. , 1988, Journal of clinical gastroenterology.
[72] I. Hirata,et al. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. , 1996, The American journal of gastroenterology.
[73] P. Tan,et al. Identification of Circulating MicroRNA Signatures for Breast Cancer Detection , 2013, Clinical Cancer Research.
[74] Mark B Pepys,et al. C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.
[75] S. Dahan,et al. MicroRNA-7 Modulates CD98 Expression during Intestinal Epithelial Cell Differentiation* , 2009, The Journal of Biological Chemistry.
[76] B. Flourié,et al. Accuracies of Serum and Fecal S100 Proteins (Calprotectin and Calgranulin C) to Predict the Response to TNF Antagonists in Patients with Crohn's Disease , 2015, Inflammatory bowel diseases.
[77] P. Lakatos,et al. The burden of inflammatory bowel disease in Europe. , 2013, Journal of Crohn's & colitis.
[78] M. Färkkilä,et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings , 2008, Alimentary pharmacology & therapeutics.
[79] H. Horvitz,et al. MicroRNA expression profiles classify human cancers , 2005, Nature.
[80] Y Raab,et al. Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis , 2002, Gut.
[81] J. Małyszko,et al. Serum Neutrophil Gelatinase-Associated Lipocalin as a Marker of Renal Function in Non-Diabetic Patients with Stage 2–4 Chronic Kidney Disease , 2008, Renal failure.
[82] Stefano Volinia,et al. MicroRNA Profiles Discriminate among Colon Cancer Metastasis , 2014, PloS one.
[83] G. Shurin,et al. C-reactive protein and lung diseases. , 2014, The international journal of biochemistry & cell biology.
[84] D. Lawlor,et al. A systematic review of the association between circulating concentrations of C reactive protein and cancer , 2007, Journal of Epidemiology and Community Health.
[85] Kazutaka Saito,et al. C-reactive protein as a biomarker for urological cancers , 2011, Nature Reviews Urology.
[86] L. Kjeldsen,et al. Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. , 2000, Biochimica et biophysica acta.
[87] P. Renzulli,et al. Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C‐reactive protein, and blood leukocytes , 2009, Inflammatory bowel diseases.
[88] Subrata Ghosh,et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.
[89] M. Färkkilä,et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings , 2008, Inflammatory bowel diseases.
[90] M. Neurath,et al. RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.
[91] R. Søkilde,et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). , 2011, Blood.
[92] E. Ogier-Denis,et al. Identification of Restricted Subsets of Mature microRNA Abnormally Expressed in Inactive Colonic Mucosa of Patients with Inflammatory Bowel Disease , 2010, PloS one.
[93] G. Porro,et al. Serum protein profiling of early and advanced stage Crohn's disease , 2014 .
[94] P. Rutgeerts,et al. Diagnostic approach to IBD. , 2000, Hepato-gastroenterology.
[95] Z. Yamagata,et al. Neutrophil gelatinase-associated lipocalin levels associated with cardiovascular disease in chronic kidney disease patients , 2014, Clinical and Experimental Nephrology.
[96] S. Brant,et al. Identification of microRNAs associated with ileal and colonic Crohn's disease† , 2010, Inflammatory bowel diseases.